Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Feb 10, 2016; 5(1): 5-15
Published online Feb 10, 2016. doi: 10.5317/wjog.v5.i1.5
Update on human papillomavirus vaccination: Where are we now?
Eloise Chapman-Davis, Lauren E Dockery, Kendall Griffith, Caroline Stroup
Eloise Chapman-Davis, Lauren E Dockery, Kendall Griffith, Caroline Stroup, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, United States
Author contributions: Chapman-Davis E and Dockery LE contributed equally to this work with literature search, text and tables; Griffith K and Stroup C contributed to literature search and tables in certain sections of the review; Chapman-Davis E and Dockery LE made several critical corrections and revisions until the submitted version was achieved.
Conflict-of-interest statement: The above-mentioned authors of this manuscript hereby declare that they do not have any conflict-of-interest (including but not limited to commercial, personal, political, intellectual, or religious interests) related to the work submitted herein.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Eloise Chapman-Davis, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Tufts University School of Medicine, Tufts Medical Center, 800 Washington Street #232, Boston, MA 02111, United States. eloise.chapman@gmail.com
Telephone: +1-617-6366058 Fax: +1-617-6363258
Received: June 29, 2015
Peer-review started: July 3, 2015
First decision: September 22, 2015
Revised: October 16, 2015
Accepted: November 24, 2015
Article in press: November 25, 2015
Published online: February 10, 2016
Processing time: 216 Days and 8.1 Hours
Core Tip

Core tip: Human papilloma virus (HPV) represents the major cause of pre-invasive and invasive lesions of the urogenital tract. This article will review the efficacy, safety and approval of the currently available vaccines against HPV including the bivalent, quadrivalent and nine-valent vaccines. Indications for use in men, immunocompromised individuals and older cohorts will also be discussed. Additionally a summary of worldwide vaccination practices, cost effectiveness, vaccination and methods to improve vaccination uptake and acceptance will be reviewed.